💊
💊Opdivo® (Nivolumab) Intravenous Infusion Approved in Taiwan for Expanded Use in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated with Platinum-based Therapy 20171107
💊
Month: November 2017
💊Opdivo (nivolumab) Demonstrates Superior Three-Year Survival Benefit for Patients with Previously Treated Advanced Renal Cell Carcinoma (RCC)
🔬Exclusive Global License for New Method of iPS Cell Production Obtained
📡Fujitsu Launches Field Trial of Ultra High-Density Distributed Antenna Systems for 5G 2017年11月7日
🎗Mitsubishi Electric Introduces New Edge-computing Software and Products